List clinical trials by disease

Clinical Trials

List clinical trials by disease

The results of your search are listed below. To view the details of a trial or study, click on the "SEE DETAILS" button. Or start a new search.

Searched for: Prostate Cancer. 23 results shown below.
CYT107 After Vaccine Treatment (Provenge) in Patients With Metastatic Hormone-Resistant Prostate Cancer
Complete title: A Phase 2 Study of Recombinant Glycosylated Human Interleukin-7 (CYT107) after Completion of Standard FDA Approved therapy with Sipuleucel-T (Provenge®) for Patients with Asymptomatic or Minimally Symptomatic Metastatic Castration-resistant Prostate Cancer (mCRPC)

Principal Investigator: Evan Yu, MD

Study Number: 8037A

Phase: II



Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer With Correlative Assessment of Androgen Receptor Signaling
Complete title: Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer (CRPC) with Correlative Assessment of Androgen Receptor (AR) Signaling and Whole-exome and Transcriptome Sequencing

Principal Investigator: Robert Montgomery, MD

Study Number: 9055

Phase: II



Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Hormone-Resistant Prostate Cancer
Complete title: A Phase I/II Trial of Concurrent Chemohormonal therapy using Enzalutamide (MDV-3100) and Cabazitaxel in Patients with Metastatic Castration Resistant Prostate Cancer

Principal Investigator: Heather Cheng

Study Number: 9279

Phase: I/II



Pilot Study of Mobilization and Treatment of Disseminated Tumor Cells in Men With Metastatic Prostate Cancer
Complete title: A Pilot Study of Mobilization and Treatment of Disseminated Tumor Cells in Men with Metastatic Prostate Cancer

Principal Investigator: Michael Schweizer

Study Number: 9297

Phase: Pilot



Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer (PARTIQoL)
Complete title: PARTIQol: Prostate Advance Radiation Technologies Investigating Quality of Life: A Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer

Principal Investigator: Jing Zeng

Study Number: 9328

Phase: III



Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance (Transformer)
Complete title: A Randomized Phase II Study Comparing Bipolar Androgen Therapy vs. Enzalutamide in Asymptomatic Men with Castration Resistant Metastatic Prostate Cancer: The TRANSFORMER Trial (Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance)

Principal Investigator: Michael Schweizer

Study Number: 9342

Phase: II



Diet and Exercise Program in Promoting Weight Loss and Improving Health in Patients With Low- or Low-Intermediate-Risk Prostate Cancer (PALS)
Complete title: PALS: Prostate Cancer Active Lifestyle Study

Principal Investigator: Jonathan Wright

Study Number: 9369

Phase: NA



Docetaxel and Carboplatin in Treating Patients With Metastatic, Hormone Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway
Complete title: A Pilot Study of Docetaxel and Carboplatin for Treatment of Patients with Metastatic, Castration Resistant Prostate Cancer Containing Biallelic Inactivation of Genes in the BRCA1/2 Pathway

Principal Investigator: Heather Cheng

Study Number: 9381

Phase: Pilot



Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Complete title: A Phase 1-2 Study of Sirolimus, Docetaxel and Carboplatin for Treatment of Patients with Metastatic, Castration Resistant Prostate Cancer: (Rapamycin inhibition of DDSP (RID)

Principal Investigator: Robert Montgomery, MD

Study Number: 9388

Phase: I/II



A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF
Complete title: A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD), With or Without Granulocyte Macrophage Colony-Stimulating Factor Adjuvant, in Patients with Metastatic Prostate Cancer

Principal Investigator: Michael Schweizer

Study Number: 9389

Phase: I



Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer
Complete title: A Phase I Study of Niclosamide in Combination with Enzalutamide in Men with Castration-Resistant Prostate Cancer

Principal Investigator: Michael Schweizer

Study Number: 9390

Phase: I



ARN-509 in Treating Patients With Prostate Cancer Who Are in Active Surveillance
Complete title: A Phase 2 Study of ARN-509 in Active Surveillance Patients

Principal Investigator: Michael Schweizer

Study Number: 9582

Phase: II



A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy
Complete title: A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men with Localized Prostate Cancer Pre-Prostatectomy

Principal Investigator: Michael Schweizer

Study Number: 9628

Phase: II



Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
Complete title: Molecular Correlates of Sensitivity and Resistance to Therapy in Genitourinary Malignancy

Principal Investigator: Robert Montgomery, MD

Study Number: 6932

Phase: NA



AZD8186 First Time In Patient Ascending Dose Study
Complete title: A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD8186 in Patients with Advanced Castration-resistant Prostate Cancer (CRPC), Squamous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients with Known PTEN-deficient/mutated or PIK3CB Mutated Advance Solid Malignancies, with Expansion to Assess the Pharmacodynamic Activity of AZD8186

Principal Investigator: Tia Higano, MD

Study Number: 20131275

Phase: I



MSB0010718C in Solid Tumors
Complete title: A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications

Principal Investigator: Nora Disis, MD

Study Number: 20132079

Phase: I



Study of MOR209/ES414 in Metastatic Castration-Resistant Prostate Cancer
Complete title: A Phase I Study of ES414 In Patients with Metastatic Castration-Resistant Prostate Cancer

Principal Investigator: Tia Higano, MD

Study Number: 20142613

Phase: I



Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer
Complete title: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies

Principal Investigator: Keith Eaton, MD, PhD

Study Number: 20150094

Phase: I



Once-daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone
Complete title: A Single-arm, Phase 2 Study to Evaluate the Safety and Efficacy of VT-464 in Patients with Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.

Principal Investigator: Robert Montgomery, MD

Study Number: 20151131

Phase: II



A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)
Complete title: A Phase I Study to Evaluate The Safety, PHarmacokinetics and PHarmacodynamics of Escalating Doses of a Vaccine-Based Immunotherapy Regimen (VBIR) for Prostate Cancer (PF-06753512)

Principal Investigator: Tia Higano, MD

Study Number: 20151318

Phase: I



Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer
Complete title: A Phase I/II open-label study to assess the safety, pharmacokinetics, and antitumor activity of oral EPI-506 in patients with metastatic castration-resistant prostate cancer

Principal Investigator: Robert Montgomery, MD

Study Number: 20152018

Phase: I/II



Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
Complete title: Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)

Principal Investigator: Evan Yu, MD

Study Number: 20162991

Phase: I/II



Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
Complete title: A PHASE IB, OPEN-LABEL STUDY OF THESAFETY AND TOLERABILITY OF ATEZOLIZUMAB IN COMBINATION WITH RADIUM-223 DICHLORIDE IN PATIENTS WITH CASTRATE-RESISTANT PROSTATE CANCER WHO HAVE PROGRESSED FOLLOWING TREATMENT WITH AN ANDROGEN PATHWAY INHIBITOR

Principal Investigator: Tia Higano, MD

Study Number: 20170291

Phase: I



Search all clinical trials

Select a disease from the list below:

Limit results to studies enrolling:

OR

Search by Keyword, Investigator Name or Study ID#:

Limit results to studies enrolling:

OR

View all studies

Limit results to studies enrolling:

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials